[
  {
    "ts": "2025-11-18T11:30:00+00:00",
    "headline": "Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody™ Duo molecules, a new class of AI-designed bispecific binding proteins.",
    "url": "https://finance.yahoo.com/news/bio-techne-licenses-ai-designed-113000353.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "8a290731-aa78-39f0-ae29-99bc9fd340fa",
      "content": {
        "id": "8a290731-aa78-39f0-ae29-99bc9fd340fa",
        "contentType": "STORY",
        "title": "Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio",
        "description": "",
        "summary": "Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody™ Duo molecules, a new class of AI-designed bispecific binding proteins.",
        "pubDate": "2025-11-18T11:30:00Z",
        "displayTime": "2025-11-18T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/012ee686bfc35748f42151baa25ae413",
          "originalWidth": 400,
          "originalHeight": 97,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qWoHPRJAH2NMSE80OLNF1Q--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/012ee686bfc35748f42151baa25ae413.cf.webp",
              "width": 400,
              "height": 97,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HXsJsg3TI9mMOcaOtRzVrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/012ee686bfc35748f42151baa25ae413.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bio-techne-licenses-ai-designed-113000353.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bio-techne-licenses-ai-designed-113000353.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TECH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]